Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1012187

Comparison of Peak and trough Concentrations of Dabigatran, Rivaroxaban and Apixaban with the Published Expected Values in Patients with Non Valvular Atrial Fibrillation


Margetić, Sandra; Ćelap, Ivana; Brčić, Marija; Mihić, Roman
Comparison of Peak and trough Concentrations of Dabigatran, Rivaroxaban and Apixaban with the Published Expected Values in Patients with Non Valvular Atrial Fibrillation // Research and Practice in Thrombosis and Haemostasis / Cushman, Mary (ur.).
Medford: Wiley Periodicals, 2019. str. 3-4 doi:10.1002/rth2.12229 (poster, međunarodna recenzija, sažetak, znanstveni)


CROSBI ID: 1012187 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Comparison of Peak and trough Concentrations of Dabigatran, Rivaroxaban and Apixaban with the Published Expected Values in Patients with Non Valvular Atrial Fibrillation

Autori
Margetić, Sandra ; Ćelap, Ivana ; Brčić, Marija ; Mihić, Roman

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Research and Practice in Thrombosis and Haemostasis / Cushman, Mary - Medford : Wiley Periodicals, 2019, 3-4

Skup
The XXVII Congress of the International Society on Thrombosis and Haemostasis

Mjesto i datum
Melbourne, Australija, 6-10.07.2019

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
dabigatran, rivaroxaban, apixaban, concentration, NVAF

Sažetak
Background : Direct oral anticoagulants (DOACs), dabigatran, rivaroxaban and apixaban, have been increasingly used for the prevention and treatment of thromboembolic diseases in recent years. However, peak and trough concentrations of these DOACs in certain clinical indications are still insufficiently investigated. Aims : The aim was to assess both peak and trough plasma concentrations of all three DOACs in patients treated for non valvular atrial fibrillation (NVAF) and to compare our own results with the first published expected values. Methods : The study included plasma samples from patients treated for NVAF and taking dabigatran (N=37), rivaroxaban (N=28) and apixaban (N=36). Blood samples were taken on the same day to obtain both trough (immediately prior the next drug dose) and peak (two hours after drug administration) DOACs concentrations. Rivaroxaban and apixaban concentrations were measured using chromogenic anti- FXa assay (Innovance anti- FXa, Siemens Healthineers, Germany) calibrated with specific calibrators for rivaroxaban and apixaban (Hyphen BioMed, France). Dabigatran was measured using commercial chromogenic method (Innovance DTI assay, Siemens Healthineers, Germany). All coagulation assays were performed on Behring Coagulation System XP (BCSXP) analyser (Siemens Healthineers, Germany). Statistical analysis was done using Mann- Whitney test by MedCalc Statistical Software version 11.5.1. The study was funded as an integral part of the Croatian Science Foundation research project IP- 2016- 06- 8208. Results : Concentrations for all three DOACs ranged as follows: dabigatran (peak 14- 415 ng/mL ; trough 0- 237 ng/mL) ; rivaroxaban (peak 90- 417 ng/mL ; trough 1- 188 ng/mL) and apixaban (peak 60- 385 ng/ mL ; trough 13- 221 ng/mL) with statistically significant differences between peak and trough concentrations (P< 0.001) for all three DOACs (Table 1). Peak and trough concentrations obtained in our study for all three DOACs conformed with published expected values for most samples analyzed (Table 1). Conclusions : The study showed a good agreement of both peak and trough concentrations for dabigatran, rivaroxaban and apixaban with the published expected values in NVAF patients.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita



POVEZANOST RADA


Projekti:
HRZZ-IP-2016-06-8208 - Novi oralni antikoagulansi: povezanost koncentracije lijeka i antikoagulantnog učinka (LAB-NOAC) (Margetić, Sandra, HRZZ - 2016-06) ( POIROT)

Ustanove:
KBC "Sestre Milosrdnice"

Profili:

Avatar Url Ivana Ćelap (autor)

Avatar Url Sandra Margetić (autor)

Citiraj ovu publikaciju

Margetić, Sandra; Ćelap, Ivana; Brčić, Marija; Mihić, Roman
Comparison of Peak and trough Concentrations of Dabigatran, Rivaroxaban and Apixaban with the Published Expected Values in Patients with Non Valvular Atrial Fibrillation // Research and Practice in Thrombosis and Haemostasis / Cushman, Mary (ur.).
Medford: Wiley Periodicals, 2019. str. 3-4 doi:10.1002/rth2.12229 (poster, međunarodna recenzija, sažetak, znanstveni)
Margetić, S., Ćelap, I., Brčić, M. & Mihić, R. (2019) Comparison of Peak and trough Concentrations of Dabigatran, Rivaroxaban and Apixaban with the Published Expected Values in Patients with Non Valvular Atrial Fibrillation. U: Cushman, M. (ur.)Research and Practice in Thrombosis and Haemostasis doi:10.1002/rth2.12229.
@article{article, editor = {Cushman, M.}, year = {2019}, pages = {3-4}, DOI = {10.1002/rth2.12229}, keywords = {dabigatran, rivaroxaban, apixaban, concentration, NVAF}, doi = {10.1002/rth2.12229}, title = {Comparison of Peak and trough Concentrations of Dabigatran, Rivaroxaban and Apixaban with the Published Expected Values in Patients with Non Valvular Atrial Fibrillation}, keyword = {dabigatran, rivaroxaban, apixaban, concentration, NVAF}, publisher = {Wiley Periodicals}, publisherplace = {Melbourne, Australija} }
@article{article, editor = {Cushman, M.}, year = {2019}, pages = {3-4}, DOI = {10.1002/rth2.12229}, keywords = {dabigatran, rivaroxaban, apixaban, concentration, NVAF}, doi = {10.1002/rth2.12229}, title = {Comparison of Peak and trough Concentrations of Dabigatran, Rivaroxaban and Apixaban with the Published Expected Values in Patients with Non Valvular Atrial Fibrillation}, keyword = {dabigatran, rivaroxaban, apixaban, concentration, NVAF}, publisher = {Wiley Periodicals}, publisherplace = {Melbourne, Australija} }

Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font